We've gone ahead and answered some of the questions you may have...
Global Mogul is a fractional investment platform for global commercial real estate and an international real estate fund that connects investors with high-yield, collateral-backed development loans and exclusive property opportunities in Latin America; primarily Colombia, Mexico, Panama, and soon in Asia.
Global Mogul was founded by JC Vasquez, a capital raising expert with over a decade of experience in securing funding for high-growth ventures, with a passion for creating wealth-building opportunities that are secure, global, and scalable.
Our mission is simple: help investors grow and protect their wealth while gaining access to borderless opportunities that build lasting legacies for themselves and their families.
Our corporate structure includes a Delaware C-Corp holding company, a Puerto Rico LP feeder fund, a Colombian SAS, and an upcoming BVI master fund. This structure optimizes tax efficiency, investor protection, and operational flexibility.
To become the premier global investment platform for borderless living, combining real estate, fintech, hospitality, and lifestyle into a single ecosystem.
We combine high-yield returns, collateral protection, lifestyle perks, and global market access — all in a structure that’s built for both wealth growth and wealth preservation.
Global Mogul exists to connect ambitious investors with the fastest-growing real estate and private investment opportunities in Latin America. We secure high-yield returns by lending to top-tier developers and acquiring premium hospitality and residential assets; all while protecting investor capital with strong collateral. Our model combines private equity discipline, venture-style upside, and the security of hard assets. The big idea is simple: deliver double-digit returns, asset-backed security, and global lifestyle perks in one investment platform.
The window is open, but it will not stay that way. Latin America is entering a historic economic expansion driven by nearshoring, digital adoption, tourism booms, and urban migration. Real estate values are still undervalued compared to global norms, but foreign capital is flowing in at record speed. Those who position themselves now will ride the wave of appreciation and income for the next decade. Waiting means paying more and earning less.
* High Growth – GDP growth in key markets like Colombia, Mexico, and Panama outpaces much of the developed world.
* Undervalued Assets – Premium real estate in prime locations is still a fraction of U.S. or European prices.
* Strong Demographics – Young, urbanizing populations fuel housing demand.
* Tourism Surge – Post-pandemic travel is pushing record tourism numbers, especially in luxury segments.
* Pro-Investment Policies – Residency programs, tax incentives, and foreign-investment-friendly laws make entry simple.
Colombia:
* 5 years: Medellín, Cartagena, and coastal zones see sustained price appreciation as tourism and expat inflows increase.
* 10 years: Colombia positions as the “Mediterranean of the Americas,” with mature luxury real estate and stable investor demand.
Mexico:
* 5 years: Nearshoring boom drives industrial and residential growth in cities like Monterrey, Tulum, and Mexico City.
* 10 years: Mexico cements itself as a global manufacturing and tourism powerhouse with significant real estate appreciation.
Panama:
* 5 years: Infrastructure expansion and Canal-related trade growth boost Panama City and coastal property markets.
* 10 years: Panama becomes the Singapore of the Americas — a global logistics and finance hub with prime asset values.
1. Asset-Backed Security: Developer loans are fully collateralized (100%–200% of loan value).
2. High-Yield Passive Income: Up to 15% APY distributed quarterly or annually.
3. First-Mover Advantage: We target undervalued, high-growth Latin markets before mainstream capital floods in.
4. Dual Strategy: Lending for predictable returns + equity in premium hospitality assets for long-term upside.
5. Global Lifestyle Perks: Investors gain access to our resorts, residences, and members’ club benefits.
* Global Mogul Holding Co. (Delaware C-Corp) – Oversees global operations and intellectual property.
* Puerto Rico Feeder Fund (LP) – U.S. investor entry point with tax-efficient distributions.
* BVI Master Fund – Centralized investment pool holding Latin American assets and loans.
* Colombian SAS / Local Entities – Hold property titles, register mortgages, and manage operations on the ground.
The Puerto Rico LP allows U.S. investors to participate in Global Mogul with tax-efficient returns under U.S. law, while streamlining compliance and administration. It bridges mainland U.S. capital to offshore growth with minimal friction.
The BVI structure offers flexibility, privacy, and global investor access. It allows both U.S. and non-U.S. investors to participate through a neutral jurisdiction while consolidating operations in the master fund for efficiency and scalability.
1. Up to 15% APY on secured developer loans.
2. 100%–200% collateral coverage for capital protection.
3. Exposure to booming Latin American real estate before the market peaks.
4. Dual income & growth strategy – lending plus equity in hospitality assets.
5. Global lifestyle perks for investors (stay, use, or rent).
6. Tax-efficient structures for both U.S. and international investors.
7. Experienced management team with deep capital markets and real estate expertise.
8. Diversification across multiple countries and asset types.
9. First-mover advantage in high-growth, undervalued markets.
10. Aligned incentives – we invest alongside our investors.
The minimum investment is $25,000 USD.
Investors are investing in Global Mogul Holding Co., this is a ground-floor opportunity to make one investment and own a piece of the fund, the fractional investing platform and the hotels, residences and more.
A SAFE (Simple Agreement for Future Equity) is an investment contract that gives investors the right to receive equity in a company in the future, typically when the company raises its next funding round. SAFE investors don’t get shares right away—they convert their investment into equity later, often at a discount or with a valuation cap. It’s a fast, founder-friendly alternative to traditional equity rounds.
A SAFE discount is a percentage reduction in the share price that SAFE investors receive when their investment converts to equity. For example, if the next funding round values shares at $1.00 and the SAFE has a 20% discount, the investor gets shares at $0.80 each. This rewards early investors for taking on more risk before the company’s valuation increases.
A pre-seed round is one of the earliest stages of startup fundraising, typically before the business is fully operational. It’s used to fund product development, market research, and initial operations. Investors at this stage; like those in Global Mogul’s early raises... get in at a lower valuation, which means potentially higher returns if the company grows.
A Regulation D offering is a type of private placement that allows companies to raise capital from accredited investors without going through the full SEC registration process. Global Mogul uses Reg D to efficiently raise funds while still meeting U.S. securities regulations. It’s only open to accredited investors who meet certain income or net worth requirements.
Our best advice is to use our third-party verification letterInstead of uploading personal documents, we recommend seeking one of these professionals to review your personal documents and complete this standard template letter:
CPA
Accountant
Lawyer
Investment Advisor
Broker-Dealer
Accredited investor criteria for individual:
Has a net worth higher than $1,000,000 either individually or with your spouse, not including your primary residence
Has an annual income higher than $200,000 for individuals
or $300,000 as joint income in the last 2 years and expect to earn more than that amount in this given year.
Is an investment professional in good standing, who holds the general securities representative license (Series 7), the investment adviser representative license (Series 65), or the private securities offerings representative license (Series 82)
Accredited investor criteria for an entity:
An entity owning investments in excess of $5 million
An entity where all equity owners are accredited investors
The following entities with assets in excess of $5 million:
Trusts
corporations
partnerships
LLCs
501(c)(3) organizations
employee benefit plans“family office” and any “family client” of that office
Investment advisers (SEC- or state-registered or exempt reporting advisers) and SEC-registered broker-dealers
Financial entities, such as:
a bank
savings and loan association
insurance company
registered investment company
business development company, or small business investment company, or rural business investment company
Yes. We work with accredited investors worldwide.
Investors in our pre-seed Reg D offering get the privilege of owning a piece of everything Global Mogul owns, this includes all of our future properties.
Contact our investor relations team, complete our accredited investor verification, review and sign the subscription agreement, and fund your investment.
We have a 1 year holding period for this offering. However, we are planning to launch our Reg CF round within 6-12 months. We are offering equity for the Reg CF round. Investors can sell then but we suggest typical terms are 24–48 months, to fully capitalize on our upcoming valuations. This is not investment advice. Contact your professional for all investment advice.
A SAFE, or Simple Agreement for Future Equity, is an investment contract used in early-stage financing rounds, particularly in startup fundraising. It's a relatively new instrument compared to traditional equity financing options like convertible notes or preferred stock.
A SAFE allows an investor to make a cash investment in a company with the expectation of receiving equity in the company at a later date, typically during a future priced equity round or upon a specific liquidity event, such as an acquisition or IPO. However, unlike a convertible note, a SAFE does not accrue interest or have a maturity date.
Key features of a SAFE:
Future Equity: The investor receives the right to obtain equity in the company at a future financing round or liquidity event, typically at a discount or with a valuation cap negotiated at the time of the SAFE agreement.
Simplicity: SAFEs are designed to be simpler and easier to understand compared to traditional equity financing documents, reducing legal complexity and negotiation time.
No Interest or Maturity Date: Unlike convertible notes, SAFEs do not accrue interest, nor do they have a maturity date by which the company must repay the investment if a qualifying event hasn't occurred.
Investor Protections: Depending on the terms negotiated, SAFEs may include investor-friendly provisions such as valuation caps, discount rates, and pro-rata rights in future financing rounds.
Lack of Voting Rights and Dividends: Typically, SAFEs do not grant investors voting rights or entitlement to dividends until the conversion event occurs.
This website and related materials are intended solely for informational purposes and do not constitute an offer to sell or a solicitation of an offer to buy any securities. Any offer to invest will be made only through official offering documents and only to individuals who qualify as accredited investors under SEC Regulation D, Rule 506(c). All investments involve risk, including the possible loss of principal. Past performance is not indicative of future results. Prospective investors should consult with their financial and legal advisors before making any investment decisions.
This website contains predictive or “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of current or historical fact contained in this website, including statements that express our intentions, plans, objectives, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions are forward-looking statements. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “will,” “should,” “would” and similar expressions are intended to identify forward-looking statements. These statements are based on current expectations, estimates and projections made by management about our business, our industry and other conditions affecting our financial condition, results of operations or business prospects. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed or forecasted in, or implied by, the forward-looking statements due to numerous risks and uncertainties. Factors that could cause such outcomes and results to differ include, but are not limited to, risks and uncertainties arising from: our ability to raise sufficient capital to execute our business plan; expectations for the clinical and pre-clinical development, manufacturing, regulatory approval, and commercialization of our pharmaceutical product candidate or any other products we may acquire or in-license; our use of clinical research centers and other contractors; expectations for incurring capital expenditures to expand our research and development and manufacturing capabilities; expectations for generating revenue or becoming profitable on a sustained basis; expectations or ability to enter into marketing and other partnership agreements; expectations or ability to enter into product acquisition and in-licensing transactions; expectations or ability to build our own commercial infrastructure to manufacture, market and sell our product candidates; acceptance of our products by doctors, patients or payors; our ability to compete against other companies and research institutions; our ability to secure adequate protection for our intellectual property; our ability to attract and retain key personnel; availability of reimbursement for our products; expected losses; and expectations for future capital requirements. Any forward-looking statements speak only as of the date on which they are made, and we undertake no obligation to publicly update or revise any forward-looking statements to reflect events or circumstances that may arise thereafter, except as required by applicable law. Investors should evaluate any statements made by us in light of these important factors.
This website contains predictive or “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of current or historical fact contained in this website, including statements that express our intentions, plans, objectives, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions are forward-looking statements. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “will,” “should,” “would” and similar expressions are intended to identify forward-looking statements. These statements are based on current expectations, estimates and projections made by management about our business, our industry and other conditions affecting our financial condition, results of operations or business prospects. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed or forecasted in, or implied by, the forward-looking statements due to numerous risks and uncertainties. Factors that could cause such outcomes and results to differ include, but are not limited to, risks and uncertainties arising from: our ability to raise sufficient capital to execute our business plan; expectations for the clinical and pre-clinical development, manufacturing, regulatory approval, and commercialization of our pharmaceutical product candidate or any other products we may acquire or in-license; our use of clinical research centers and other contractors; expectations for incurring capital expenditures to expand our research and development and manufacturing capabilities; expectations for generating revenue or becoming profitable on a sustained basis; expectations or ability to enter into marketing and other partnership agreements; expectations or ability to enter into product acquisition and in-licensing transactions; expectations or ability to build our own commercial infrastructure to manufacture, market and sell our product candidates; acceptance of our products by doctors, patients or payors; our ability to compete against other companies and research institutions; our ability to secure adequate protection for our intellectual property; our ability to attract and retain key personnel; availability of reimbursement for our products; expected losses; and expectations for future capital requirements. Any forward-looking statements speak only as of the date on which they are made, and we undertake no obligation to publicly update or revise any forward-looking statements to reflect events or circumstances that may arise thereafter, except as required by applicable law. Investors should evaluate any statements made by us in light of these important factors.